Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Spironolactone-induced pemphigoid]

F Grange1, Y Scrivener, A Koessler

  • 1Service de Dermatologie, Hôpitaux civils de Colmar.

Annales De Dermatologie Et De Venereologie
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel).

Annales de dermatologie et de venereologie·2025
Same author

Effectiveness and safety of mogamulizumab for the treatment of Sézary syndrome in very elderly patients: A real-world, multicentre, retrospective study conducted in France.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.

Annales de dermatologie et de venereologie·2024
Same author

Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Post-traumatic ulcerated and chronic necrobiosis lipoidica of the elbow: A new entity?

Annales de dermatologie et de venereologie·2023
Same author

Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same journal

2024 guidelines (S3) for the therapeutic management of patients with genital herpes.

Annales de dermatologie et de venereologie·2026
Same journal

Topical JAK inhibitors in the lichen planus spectrum: a systematic review.

Annales de dermatologie et de venereologie·2026
Same journal

2024 recommendations for the therapeutic management of anogenital warts.

Annales de dermatologie et de venereologie·2026
Same journal

Successful use of thalidomide in treating metastatic Crohn's disease.

Annales de dermatologie et de venereologie·2026
Same journal

Multiple cutaneous juvenile xanthogranuloma: a monocentric study.

Annales de dermatologie et de venereologie·2026
Same journal

Cartilage-hair-hypoplasia associated with granulomatosis induced by rubella vaccine.

Annales de dermatologie et de venereologie·2026
See all related articles

Spironolactone use may trigger pemphigoid, a blistering skin condition. Stopping the drug led to symptom resolution in one patient, suggesting a potential causal link.

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Pemphigoid development has been sporadically linked to certain medications.
  • A recent case-control study indicated a significant association between pemphigoid and spironolactone use.

Observation:

  • An 82-year-old patient presented with bullous lesions consistent with pemphigoid.
  • The patient was on long-term treatment with multiple drugs, including spironolactone.
  • Withdrawal of spironolactone resulted in the regression of cutaneous lesions.

Findings:

  • Histology and direct cutaneous immunofluorescence confirmed pemphigoid diagnosis.
  • The patient experienced complete lesion regression and no recurrence over an 18-month follow-up after spironolactone withdrawal.

Implications:

Related Experiment Videos

  • Spironolactone's causal role in pemphigoid development is plausible, supported by this case and epidemiological data.
  • Further research is needed to confirm the causal relationship between spironolactone and pemphigoid.